Altimmune (ALT) Operating Expenses (2010 - 2026)
Altimmune (ALT) posted quarterly Operating Expenses of $24.2 million for Q1 2026, up 11.11% year-over-year from $21.8 million in Q1 2025, and down 16.17% quarter-over-quarter from $28.9 million in Q4 2025.
Altimmune (ALT) Operating Expenses (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Operating Expenses for 17 consecutive years, with $24.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 11.11% year-over-year to $24.2 million; the TTM figure through Mar 2026 stood at $97.0 million (down 1.28% YoY), while the FY2025 annual figure was $94.5 million, down 8.39% from the prior year.
- Operating Expenses fell to $24.2 million in Q1 2026 per ALT's latest filing, from $28.9 million in the prior quarter.
- Across five years, Operating Expenses topped out at $33.7 million in Q4 2023 and bottomed at $18.0 million in Q2 2023.
- Historically, Operating Expenses has averaged $23.9 million across 5 years, with a median of $23.0 million in 2022.
- On a YoY basis, Operating Expenses climbed as much as 48.5% in 2024 and fell as far as 26.11% in 2024.
- Altimmune's Operating Expenses stood at $23.0 million in 2022, then jumped by 46.45% to $33.7 million in 2023, then decreased by 26.11% to $24.9 million in 2024, then advanced by 16.28% to $28.9 million in 2025, then retreated by 16.17% to $24.2 million in 2026.
- Business Quant data shows ALT's Operating Expenses at $24.2 million in Q1 2026, $28.9 million in Q4 2025, and $20.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | 26.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.23 Mn |
| Mar 31, 2026 | 24.24 Mn |
| Dec 31, 2025 | 28.92 Mn |
| Sep 30, 2025 | 20.86 Mn |
| Jun 30, 2025 | 22.93 Mn |
| Mar 31, 2025 | 21.82 Mn |
| Dec 31, 2024 | 24.87 Mn |
| Sep 30, 2024 | 24.77 Mn |
| Jun 30, 2024 | 26.75 Mn |
| Mar 31, 2024 | 26.80 Mn |
| Dec 31, 2023 | 33.66 Mn |
| Sep 30, 2023 | 22.90 Mn |
| Jun 30, 2023 | 18.01 Mn |
| Mar 31, 2023 | 21.78 Mn |
| Dec 31, 2022 | 22.98 Mn |
| Sep 30, 2022 | 24.75 Mn |
| Jun 30, 2022 | 20.40 Mn |
| Mar 31, 2022 | 19.53 Mn |
| Dec 31, 2021 | 27.26 Mn |
| Sep 30, 2021 | 33.36 Mn |